PT-141 (Bremelanotide) vs Nonapeptide-1
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
PT-141 (Bremelanotide)Skin & Cosmetic
Nonapeptide-1- Summary
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- Nonapeptide-1 is a synthetic 9-amino acid peptide that inhibits melanin production by blocking α-MSH (alpha-melanocyte stimulating hormone) receptor binding. Used in cosmetic formulations for skin lightening and evening skin tone, it is particularly effective for UV-induced and hormonal hyperpigmentation.
- Half-Life
- 2–3 hours
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 0.5–1.75 mg
- 0.05–0.5% concentration in formulation
- Frequency
- As needed (not daily)
- Twice daily
- Key Benefits
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- Inhibits UV-induced tanning and hyperpigmentation
- Reduces hormonal melasma
- Evens skin tone at receptor level
- Well-tolerated with minimal irritation
- Complementary to tyrosinase inhibitors for enhanced brightening
- Reduces post-inflammatory hyperpigmentation
- Side Effects
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Generally very well-tolerated
- Rare contact sensitivity in susceptible individuals
- Theoretical risk of excessive depigmentation with prolonged high-concentration use
- Stacks With
- —
- —